Carlos A. Castañeda

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

S.J. Luen, Roberto Salgado, Maria Vittoria Dieci et al. · Annals of Oncology · 2018 · 196 citations · Full text

Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group

S. Swisher, Yun Wu, Carlos A. Castañeda et al. · Annals of Surgical Oncology · 2016 · 124 citations

Breast Oncology, Cancer Detection, Medicine +5

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Cristina Saura, Dominik Hlauschek, Mafalda Oliveira et al. · The Lancet Oncology · 2019 · 95 citations

Breast Oncology, Endocrine-related Cancer, Taselisib Versus +11

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

Angelo Gámez‐Pozo, Julia Berges‐Soria, Jorge M. Arevalillo et al. · Cancer Research · 2015 · 68 citations · Full text

Clinical Implications, Unique Metabolic Profile, Engineering +20

Distribution of Tumor-Infiltrating Immune Cells in Glioblastoma

Enrique Orrego, Carlos A. Castañeda, Miluska Castillo et al. · CNS Oncology · 2018 · 62 citations · Full text